(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Akerna Corp., 9F, and Pinduoduo.

The three biggest losers today are Kazia Therapeutics Limited, NanoVibronix, and Kubient.

Winners today

1. Akerna Corp. (KERNW) – 63.11%

NASDAQ ended the session with Akerna Corp. jumping 63.11% to $0.02 on Wednesday while NASDAQ jumped 0.29% to $14,281.76.

Yearly Top and Bottom Value

Akerna Corp.’s stock is valued at $0.02 at 01:32 EST, way above its 52-week high of $0.02.

More news about Akerna Corp..

2. 9F (JFU) – 22.3%

9F Inc., together with its subsidiaries, operates a digital financial account platform that integrates and personalizes financial services in the People's Republic of China. Its products include digital financial accounts that offer online lending, online wealth management, and payment facilitation services; revolving and non-revolving loan products to borrowers, as well as traffic referral services to institutional funding partners; and a suite of online wealth management products, such as fixed income products, stocks, insurance, and mutual funds to investors in various platforms, including Wukong Licai, 9F Wallet, and 9F Puhui. The company also provides payment facilitation and other products and services that help users to pay credit card bills and household bills, such as utility bills; and other value-added services, including credit history search, debt consolidation, and user referral services. It has partnerships with borrowers, investors, financial institutions, and merchant partners. The company was formerly known as JIUFU Financial Technology Service Limited and changed its name to 9F Inc. in June 2014. 9F Inc. was founded in 2006 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with 9F jumping 22.3% to $4.25 on Wednesday while NASDAQ jumped 0.29% to $14,281.76.

Earnings Per Share

As for profitability, 9F has a trailing twelve months EPS of $-7.17.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.06%.

Volatility

9F’s last week, last month’s, and last quarter’s current intraday variation average was 13.17%, 2.49%, and 3.82%.

9F’s highest amplitude of average volatility was 13.17% (last week), 4.68% (last month), and 3.82% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 36.5%, now sitting on 561.67M for the twelve trailing months.

More news about 9F.

3. Pinduoduo (PDD) – 18.43%

PDD Holdings Inc., a multinational commerce group, owns and operates a portfolio of businesses. It operates Pinduoduo, an e-commerce platform that offers products in various categories, including agricultural produce, apparel, shoes, bags, mother and childcare products, food and beverage, electronic appliances, furniture and household goods, cosmetics and other personal care, sports and fitness items and auto accessories; and Temu, an online marketplace. It focuses on bringing businesses and people into the digital economy. The company was formerly known as Pinduoduo Inc. and changed its name to PDD Holdings Inc. in February 2023. PDD Holdings Inc. was incorporated in 2015 and is based in Dublin, Ireland.

NASDAQ ended the session with Pinduoduo rising 18.43% to $139.41 on Wednesday while NASDAQ jumped 0.29% to $14,281.76.

Earnings Per Share

As for profitability, Pinduoduo has a trailing twelve months EPS of $3.87.

PE Ratio

Pinduoduo has a trailing twelve months price to earnings ratio of 36.02. Meaning, the purchaser of the share is investing $36.02 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.92%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 3.9% and positive 9.2% for the next.

Volatility

Pinduoduo’s last week, last month’s, and last quarter’s current intraday variation average was 0.58%, 0.49%, and 2.01%.

Pinduoduo’s highest amplitude of average volatility was 0.58% (last week), 1.75% (last month), and 2.01% (last quarter).

Sales Growth

Pinduoduo’s sales growth is 46.9% for the present quarter and 59.5% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Pinduoduo’s stock is considered to be oversold (<=20).

More news about Pinduoduo.

4. Lyra Therapeutics (LYRA) – 15.97%

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

NASDAQ ended the session with Lyra Therapeutics jumping 15.97% to $3.34 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.29% to $14,281.76, after two successive sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Lyra Therapeutics has a trailing twelve months EPS of $-1.4.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.6%.

Yearly Top and Bottom Value

Lyra Therapeutics’s stock is valued at $3.34 at 01:32 EST, way below its 52-week high of $5.25 and way higher than its 52-week low of $1.86.

More news about Lyra Therapeutics.

5. GameStop (GME) – 11.17%

GameStop Corp., a specialty retailer, provides games and entertainment products through its stores and ecommerce platforms in the United States, Canada, Australia, and Europe. The company sells new and pre-owned gaming platforms; accessories, such as controllers, gaming headsets, and virtual reality products; new and pre-owned gaming software; and in-game digital currency, digital downloadable content, and full-game downloads. It also sells collectibles comprising apparel, toys, trading cards, gadgets, and other retail products for pop culture and technology enthusiasts, as well as engages in the digital asset wallet and NFT marketplace activities. The company operates stores and ecommerce sites under the GameStop, EB Games, and Micromania brands; and pop culture themed stores that sell collectibles, apparel, gadgets, electronics, toys, and other retail products under the Zing Pop Culture brand, as well as offers Game Informer magazine, a print and digital gaming publication. The company was formerly known as GSC Holdings Corp. GameStop Corp. was founded in 1996 and is headquartered in Grapevine, Texas.

NYSE ended the session with GameStop jumping 11.17% to $13.24 on Wednesday, after five consecutive sessions in a row of losses. NYSE dropped 0.01% to $15,929.54, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, GameStop has a trailing twelve months EPS of $-0.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.64%.

Sales Growth

GameStop’s sales growth for the next quarter is negative 1.3%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GameStop’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

GameStop’s stock is valued at $13.24 at 01:32 EST, way below its 52-week high of $27.87 and way higher than its 52-week low of $11.83.

Moving Average

GameStop’s worth is under its 50-day moving average of $14.50 and way under its 200-day moving average of $19.46.

More news about GameStop.

6. MorphoSys AG (MOR) – 10.28%

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

NASDAQ ended the session with MorphoSys AG rising 10.28% to $5.15 on Wednesday while NASDAQ jumped 0.29% to $14,281.76.

Earnings Per Share

As for profitability, MorphoSys AG has a trailing twelve months EPS of $0.73.

PE Ratio

MorphoSys AG has a trailing twelve months price to earnings ratio of 7.05. Meaning, the purchaser of the share is investing $7.05 for every dollar of annual earnings.

Moving Average

MorphoSys AG’s worth is way under its 50-day moving average of $6.86 and way under its 200-day moving average of $6.40.

Sales Growth

MorphoSys AG’s sales growth is negative 31.5% for the ongoing quarter and negative 11.8% for the next.

Yearly Top and Bottom Value

MorphoSys AG’s stock is valued at $5.15 at 01:32 EST, way under its 52-week high of $8.67 and way higher than its 52-week low of $3.17.

Earnings Before Interest, Taxes, Depreciation, and Amortization

MorphoSys AG’s EBITDA is 0.91.

More news about MorphoSys AG.

7. Medigus Ltd. (MDGS) – 9.03%

Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it provides digital advertising platform; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, and visualization solutions; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.

NASDAQ ended the session with Medigus Ltd. rising 9.03% to $3.18 on Wednesday, after three consecutive sessions in a row of gains. NASDAQ rose 0.29% to $14,281.76, after two consecutive sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Medigus Ltd. has a trailing twelve months EPS of $-8.7.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.72%.

Moving Average

Medigus Ltd.’s worth is below its 50-day moving average of $3.39 and way under its 200-day moving average of $4.34.

Yearly Top and Bottom Value

Medigus Ltd.’s stock is valued at $3.18 at 01:32 EST, way under its 52-week high of $7.17 and way higher than its 52-week low of $2.76.

More news about Medigus Ltd..

8. Marathon (MARA) – 8.6%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon jumping 8.6% to $12.25 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.29% to $14,281.76, after two successive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-3.08.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.13%.

More news about Marathon.

9. Lazydays Holdings (LAZY) – 8.48%

Lazydays Holdings, Inc. operates recreation vehicle (RV) dealerships under the Lazydays name in the United States. It provides RV sales, RV parts and services, after-market parts and accessories, and RV camping facilities. The company offers various new and used RVs; onsite general RV maintenance and repair services; and collision repair services, as well as sells and installs various parts and accessories, such as tow hitches, satellite dishes, and suspension systems. It also operates the Lazydays RV resort at Tampa, Florida. In addition, the company arranges financing for vehicle purchases through third-party finance sources; and offers various third-party protection insurance plans and services to the purchasers of its RVs. It operates dealerships locations at The Villages, Florida; Tucson, Arizona; Minneapolis, Minnesota; Knoxville, Tennessee; and Loveland and Denver, Colorado. The company was founded in 1976 and is based in Seffner, Florida.

NASDAQ ended the session with Lazydays Holdings rising 8.48% to $6.01 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.29% to $14,281.76, after two successive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Lazydays Holdings has a trailing twelve months EPS of $-0.54.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.22%.

Yearly Top and Bottom Value

Lazydays Holdings’s stock is valued at $6.01 at 01:32 EST, way under its 52-week high of $14.36 and way higher than its 52-week low of $5.11.

Volume

Today’s last reported volume for Lazydays Holdings is 245392 which is 68.43% above its average volume of 145691.

Sales Growth

Lazydays Holdings’s sales growth is negative 2.8% for the present quarter and negative 1.2% for the next.

More news about Lazydays Holdings.

10. Plug Power (PLUG) – 7.64%

Plug Power Inc. delivers end-to-end clean hydrogen and zero-emissions fuel cell solutions for supply chain and logistics applications, on-road electric vehicles, stationary power market, and others in North America and internationally. It engages in building an end-to-end green hydrogen ecosystem, including liquid green hydrogen production, storage and handling, transportation, and dispensing infrastructure. The company offers GenDrive, a hydrogen-fueled proton exchange membrane (PEM) fuel cell system that provides power to material handling electric vehicles; GenFuel, a liquid hydrogen fueling delivery, generation, storage, and dispensing system; GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive fuel cell systems, GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products, and ProGen fuel cell engines; and GenSure, a stationary fuel cell solution that offers modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation, and utility sectors. It also provides GenKey, an integrated turn-key solution for transitioning to fuel cell power; ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; Liquefaction systems; and Electrolyzers that are hydrogen generators optimized for clean hydrogen production. The company sells its products through a direct product sales force, original equipment manufacturers, and dealer networks. Plug Power Inc. was founded in 1997 and is headquartered in Latham, New York.

NASDAQ ended the session with Plug Power rising 7.64% to $3.68 on Wednesday, after five successive sessions in a row of losses. NASDAQ rose 0.29% to $14,281.76, after two sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Plug Power has a trailing twelve months EPS of $-1.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.57%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 18.4% and 25.7%, respectively.

More news about Plug Power.

Losers Today

1. Kazia Therapeutics Limited (KZIA) – -14.57%

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

NASDAQ ended the session with Kazia Therapeutics Limited dropping 14.57% to $0.60 on Wednesday while NASDAQ rose 0.29% to $14,281.76.

Earnings Per Share

As for profitability, Kazia Therapeutics Limited has a trailing twelve months EPS of $-0.74.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -134.97%.

Moving Average

Kazia Therapeutics Limited’s value is way under its 50-day moving average of $0.76 and way below its 200-day moving average of $1.01.

Volume

Today’s last reported volume for Kazia Therapeutics Limited is 51563 which is 27.37% below its average volume of 70995.

More news about Kazia Therapeutics Limited.

2. NanoVibronix (NAOV) – -13.87%

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

NASDAQ ended the session with NanoVibronix sliding 13.87% to $1.18 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.29% to $14,281.76, after two consecutive sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, NanoVibronix has a trailing twelve months EPS of $-3.15.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -126.39%.

More news about NanoVibronix.

3. Kubient (KBNT) – -11.11%

Kubient, Inc. develops a cloud-based software platform for digital advertising industry. It develops Audience Cloud, a platform for real-time trading of programmatic advertising. The company's platform allows advertisers and publishers the ability to use machine learning during programmatic ad space auction. The company was incorporated in 2017 and is based in New York, New York.

NASDAQ ended the session with Kubient falling 11.11% to $0.00 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.29% to $14,281.76, after two sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Kubient has a trailing twelve months EPS of $-0.87.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -76.23%.

Yearly Top and Bottom Value

Kubient’s stock is valued at $0.00 at 01:32 EST, below its 52-week low of $0.00.

Moving Average

Kubient’s worth is below its 50-day moving average of $0.23 and below its 200-day moving average of $0.53.

Sales Growth

Kubient’s sales growth is negative 50% for the present quarter and 3.7% for the next.

Revenue Growth

Year-on-year quarterly revenue growth declined by 99.1%, now sitting on 1.17M for the twelve trailing months.

More news about Kubient.

4. Lion Group Holding Ltd. (LGHLW) – -10.91%

NASDAQ ended the session with Lion Group Holding Ltd. falling 10.91% to $0.00 on Wednesday while NASDAQ jumped 0.29% to $14,281.76.

Yearly Top and Bottom Value

Lion Group Holding Ltd.’s stock is valued at $0.00 at 01:32 EST, below its 52-week low of $0.00.

More news about Lion Group Holding Ltd..

5. argenx SE (ARGX) – -9.67%

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

NASDAQ ended the session with argenx SE dropping 9.67% to $447.85 on Wednesday while NASDAQ rose 0.29% to $14,281.76.

Earnings Per Share

As for profitability, argenx SE has a trailing twelve months EPS of $-4.11.

More news about argenx SE.

6. FibroGen (FGEN) – -9.03%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen sliding 9.03% to $0.44 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.29% to $14,281.76, after two sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.

Earnings Before Interest, Taxes, Depreciation, and Amortization

FibroGen’s EBITDA is 0.08.

Yearly Top and Bottom Value

FibroGen’s stock is valued at $0.44 at 01:32 EST, way under its 52-week high of $25.69 and way above its 52-week low of $0.33.

Volatility

FibroGen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.39%, a positive 0.06%, and a positive 7.52%.

FibroGen’s highest amplitude of average volatility was 1.85% (last week), 8.27% (last month), and 7.52% (last quarter).

More news about FibroGen.

7. Neoleukin Therapeutics (NLTX) – -7.91%

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

NASDAQ ended the session with Neoleukin Therapeutics dropping 7.91% to $3.27 on Wednesday while NASDAQ jumped 0.29% to $14,281.76.

Earnings Per Share

As for profitability, Neoleukin Therapeutics has a trailing twelve months EPS of $-3.07.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.88%.

Yearly Top and Bottom Value

Neoleukin Therapeutics’s stock is valued at $3.27 at 01:32 EST, way under its 52-week high of $4.70 and way above its 52-week low of $1.90.

More news about Neoleukin Therapeutics.

8. Motus GI Holdings (MOTS) – -6.54%

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida.

NASDAQ ended the session with Motus GI Holdings falling 6.54% to $4.00 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.29% to $14,281.76, after two sequential sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Motus GI Holdings has a trailing twelve months EPS of $-25.93.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 63% and 64.4%, respectively.

Volume

Today’s last reported volume for Motus GI Holdings is 45367 which is 58.64% below its average volume of 109713.

More news about Motus GI Holdings.

9. Moleculin Biotech (MBRX) – -6.45%

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

NASDAQ ended the session with Moleculin Biotech dropping 6.45% to $0.55 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.29% to $14,281.76, after two sequential sessions in a row of losses, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Moleculin Biotech has a trailing twelve months EPS of $-0.89.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -56.16%.

Yearly Top and Bottom Value

Moleculin Biotech’s stock is valued at $0.55 at 01:32 EST, way below its 52-week high of $1.65 and way above its 52-week low of $0.34.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is a negative 4.3% and positive 32.1% for the next.

More news about Moleculin Biotech.

10. Mediaco Holding (MDIA) – -6.43%

MediaCo Holding Inc. owns and operates radio stations in the United States. The company engages in the operation of WQHT-FM and WBLS-FM radio stations in the New York City area. It owns and operates advertising displays, such as bulletins, posters, and digital billboards primarily in Georgia, Alabama, South Carolina, Florida, Kentucky, West Virginia, and Ohio. The company also offers digital advertising and event, which includes sponsorships, ticket sales, licensing, and syndication services. MediaCo Holding Inc. was incorporated in 2019 and is headquartered in New York, New York.

NASDAQ ended the session with Mediaco Holding sliding 6.43% to $0.59 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.29% to $14,281.76, after two successive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Mediaco Holding has a trailing twelve months EPS of $-0.31.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.61%.

More news about Mediaco Holding.

Stay up to date with our winners and losers daily report